Pet Pharm Biotech Co (ROCO:7762) PE Ratio (TTM): 112.11 (As of Aug. 14, 2026) — 20% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7762 Pet Pharm Biotech Co Ltd ROCO:7762
17 GF Score
Price NT$50.90
! 5 Warning Signs
View Full Analysis

What is Pet Pharm Biotech Co PE Ratio (TTM)?

Pet Pharm Biotech Co ROCO:7762 +1.39% 17 PE Ratio (TTM) is 112.11 as of Aug. 14, 2026, which is 20% below its 10-year median of 140.75. GuruFocus rates ROCO:7762 with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 631 Drug Manufacturers companies, Pet Pharm Biotech Co ranks worse than 92.39% on this metric.

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-14), Pet Pharm Biotech Co's share price is NT$50.90. Pet Pharm Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.45. Therefore, Pet Pharm Biotech Co's PE Ratio (TTM) for today is 112.11.

Good Sign:

Pet Pharm Biotech Co Ltd stock PE Ratio (=110.82) is close to 2-year low of 102.98.


The historical rank and industry rank for Pet Pharm Biotech Co's PE Ratio (TTM) or its related term are showing as below:

ROCO:7762' s PE Ratio (TTM) Range Over the Past 10 Years
Min: 96.64   Med: 140.75   Max: 239.51
Current: 112.11


During the past 4 years, the highest PE Ratio (TTM) of Pet Pharm Biotech Co was 239.51. The lowest was 96.64. And the median was 140.75.


ROCO:7762's PE Ratio (TTM) is ranked worse than
92.39% of 631 companies
in the Drug Manufacturers industry
Industry Median: 21.13 vs ROCO:7762: 112.11

Pet Pharm Biotech Co's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was NT$0.30. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.45.

As of today (2026-08-14), Pet Pharm Biotech Co's share price is NT$50.90. Pet Pharm Biotech Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.45. Therefore, Pet Pharm Biotech Co's PE Ratio without NRI for today is 112.11.

During the past 4 years, Pet Pharm Biotech Co's highest PE Ratio without NRI was 240.18. The lowest was 102.98. And the median was 147.89.

Pet Pharm Biotech Co's EPS without NRI for the six months ended in Dec. 2025 was NT$0.30. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.45.

During the past 12 months, Pet Pharm Biotech Co's average EPS without NRI Growth Rate was 28.00% per year.

Pet Pharm Biotech Co's EPS (Basic) for the six months ended in Dec. 2025 was NT$0.30. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.45.


Pet Pharm Biotech Co  (ROCO:7762) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Pet Pharm Biotech Co PE Ratio (TTM) Related Terms


Pet Pharm Biotech Co PE Ratio (TTM) Historical Data

* Premium members only.

The historical data trend for Pet Pharm Biotech Co's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pet Pharm Biotech Co PE Ratio (TTM) Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
PE Ratio (TTM)
N/A N/A 109.73 150.72

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio (TTM) Get a 7-Day Free Trial N/A At Loss 109.73 At Loss 150.72

ROCO:7762 vs LLY, JNJ, ABBV: PE Ratio (TTM) Comparison

For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pet Pharm Biotech Co PE Ratio (TTM) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Pet Pharm Biotech Co's PE Ratio (TTM) falls into.


ROCO:7762
17GF Score
Pet Pharm Biotech Co Ltd ROCO:7762
PE Ratio (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pet Pharm Biotech Co PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Pet Pharm Biotech Co's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=50.90/0.454
=112.11

Pet Pharm Biotech Co's Share Price of today is NT$50.90.
For company reported semi-annually, Pet Pharm Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.45.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio (TTM) →
What does a PE Ratio (TTM) of 112.11 mean?
Pet Pharm Biotech Co (ROCO:7762) has a PE Ratio (TTM) of 112.11 as of Aug. 14, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Pet Pharm Biotech Co and its competitors. This is 20% below median its historical median of 140.75. Over the past decade, Pet Pharm Biotech Co's PE Ratio (TTM) has ranged from 96.64 to 239.51. According to the industry distribution chart, Pet Pharm Biotech Co ranks #583 out of 631 companies in the Drug Manufacturers industry, placing it in the top 92.4%.
Is Pet Pharm Biotech Co's PE Ratio (TTM) too high?
Pet Pharm Biotech Co's current PE Ratio (TTM) of 112.11 is 20% below median its 10-year median of 140.75. Over the past 10 years, this metric has ranged from a low of 96.64 to a high of 239.51. The Drug Manufacturers industry median PE Ratio (TTM) is 21.13. Pet Pharm Biotech Co's value of 112.11 is 430.6% above this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #583 out of 631 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pet Pharm Biotech Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's PE Ratio (TTM) compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #583 out of 631 companies for PE Ratio (TTM). This places Pet Pharm Biotech Co in the lower half of its industry. The industry median PE Ratio (TTM) is 21.13. Pet Pharm Biotech Co's value of 112.11 is 430.6% above this benchmark. Historically, Pet Pharm Biotech Co's own PE Ratio (TTM) has ranged from 96.64 to 239.51 over the past decade. While the company's 10-year median is 140.75 vs. the industry median of 21.13, Pet Pharm Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 21.13, based on 631 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current PE Ratio (TTM) of 112.11 is 430.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 21.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current PE Ratio (TTM) is 112.11, which is 20% below median its own 10-year median of 140.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current PE Ratio (TTM) of 112.11. The current PE Ratio (TTM) is 112.11, which is 20% below median its 10-year median of 140.75 and 430.6% above the Drug Manufacturers industry median of 21.13. Pet Pharm Biotech Co's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current PE Ratio (TTM) is 112.11 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pet Pharm Biotech Co Business Description

Address 143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
17GF Score

Get the complete analysis for ROCO:7762

PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$50.90
Price